Surgical resection of the tumor with wide margins remains the preferred method of treatment, and has shown the most success against the disease. Recently, limb-sparing surgery has been explored with moderate success. In cases of advanced, recurrent, or metastasized disease, or if the tumor is inoperable, chemotherapy and radiation are the standard of care, although the overall success rates with these remains low. In January 2020, The U.S. Food and Drug Administration approved Tazverik (tazemetostat), a compound that blocks the EZH2 methyltransferase for the treatment<unk>  in patients aged 16 years and older with either metastatic or locally advanced (unable to be completely removed surgically) disease. The effectiveness of tazemetostat is further reinforced by real world report recently published by Dr Sameer Rastogi et al.
Epithelioid sarcoma
Angiomatoid fibrous histiocytoma
Alveolar soft part sarcoma
Sclerosing epithelioid fibrosarcoma
Undifferentiated pleomorphic sarcoma
Mast cell sarcoma
Hemangiosarcoma
Adenomatoid tumor